AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy

By Reuters News

- AstraZeneca AZN.L said on Monday it has won two US drug approvals, an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder.

  • The US Food and Drug Administration approved Imfinzi, combined with enfortumab vedotin, a targeted therapy prior to surgery, for muscle-invasive bladder cancer patients who are ineligible for or have refused cisplatin-based chemotherapy

  • The Imfinzi approval was based on a late-stage trial which showed the regimen cut the risk of cancer recurrence by 49% and the risk of death by 42%

  • Imfinzi is already approved across more than 50 countries and is indicated for a range of cancers including lung and bladder

  • The FDA also approved Klygefa, developed by AstraZeneca's rare disease unit Alexion, for adults with generalised myasthenia gravis who carry antibodies that attack proteins on the nerves, disrupting communication with muscles

  • Klygefa also won approval in the EU for the same indication on Monday, adding to its clearances in Japan and other countries for certain adults with gMG

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.